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Abstract 
Purpose: Data for ANCA‑associated vasculitis (AAV) patients requiring intensive care are scarce.
Methods: We included 97 consecutive patients with acute AAV manifestations (new onset or relapsing disease), 
admitted to 18 intensive care units (ICUs) over a 10‑year period (2002–2012). A group of 95 consecutive AAV patients 
with new onset or relapsing disease, admitted to two nephrology departments with acute vasculitis manifestations, 
constituted the control group.
Results:  In the ICU group, patients predominantly showed granulomatosis with polyangiitis and proteinase‑3 
ANCAs. Compared with the non‑ICU group, the ICU group showed comparable Birmingham vasculitis activity score 
and a higher frequency of heart, central nervous system and lungs involvements. Respiratory assistance, renal replace‑
ment therapy and vasopressors were required in 68.0, 56.7 and 26.8% of ICU patients, respectively. All but one patient 
(99%) received glucocorticoids, 85.6% received cyclophosphamide, and 49.5% had plasma exchanges as remission 
induction regimens. Fifteen (15.5%) patients died during the ICU stay. The following were significantly associated with 
ICU mortality in the univariate analysis: the need for respiratory assistance, the use of vasopressors, the occurrence of 
at least one infection event in ICU, cyclophosphamide treatment, sequential organ failure assessment at admission 
and simplified acute physiology score II. After adjustment on sequential organ failure assessment or infection, cyclo‑
phosphamide was no longer a risk factor for mortality. Despite a higher initial mortality rate of ICU patients within the 
first hospital stay (p < 0.0001), the long‑term mortality of hospital survivors did not differ between ICU and non‑ICU 
groups (18.6 and 20.4%, respectively, p = 0.36). Moreover, we observed no renal survival difference between groups 
after a 1‑year follow‑up (82.1 and 80.5%, p = 0.94).
Conclusion: This study supports the idea that experiencing an ICU challenge does not impact the long‑term prog‑
nosis of AAV patients.
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Background
Anti-neutrophil cytoplasmic antibodies (ANCAs)-asso-
ciated vasculitis (AAV) are life-threatening multisys-
tem autoimmune diseases characterized by necrotizing 
inflammation of small- to medium-sized vessels [1, 2]. 
There are three differentiated entities based on clinical 
and pathological criteria: microscopic polyangiitis (MPA), 
granulomatosis with polyangiitis (GPA) and eosinophilic 
granulomatosis with polyangiitis (EGPA) [3]. Their clini-
cal spectrum partially overlaps. Indeed, rapidly progres-
sive glomerulonephritis is the typical renal presentation 
of MPA and GPA, but is rarely present in EGPA [1]. Dif-
fuse alveolar hemorrhage (DAH) is the most critical lung 
injury observed with all entities, but more frequently with 
MPA and GPA [4, 5]. Other respiratory presentations 
include pulmonary infiltrates and nodules, the latter being 
observed predominantly in GPA [6]. Even though ANCA 
negativity does not exclude AAV diagnosis, diffuse forms 
of AAV are usually associated with serum positivity for 
ANCAs [1, 7]. Given their high level of specificity, ANCA 
detection is critical for AAV diagnosis, and ANCA posi-
tivity with a compatible clinical diagnosis usually allows 
the initiation of immunosuppressive treatments [8, 9].
The prompt initiation of immunosuppressive drugs to 
induce remission is critical for AAV patient prognosis. 
In generalized and severe forms, conventional induction 
treatment combines high doses of glucocorticoids and 
cyclophosphamide [10]. In addition, plasma exchange 
(PE) may be used in severe forms with DAH and/or 
severe renal involvement [11, 12]. Based on recent clini-
cal trials, rituximab, the anti-CD20 monoclonal anti-
body, can be used as an alternative to cyclophosphamide. 
Under these regimens, AAV remission is achieved in 
60–80% of the patients [13–17]. However, despite being 
adequately treated, some patients experience resistance 
to therapy or disease relapse. Moreover, a high mortal-
ity rate is observed in AAV patients, with rates reaching 
10–15% within the first year following treatment ini-
tiation, the main causes of early death being infection 
events and vasculitis manifestations [18, 19]. Mortality 
rates of up to 20% after 5 years have been observed, and 
mortality has been shown to be higher with MPA than 
with EGPA and GPA [18].
To date, patients with the most severe forms of AAV—
those requiring intensive care—have not been extensively 
and adequately analyzed. Indeed, most previous studies 
were small size studies, uncontrolled and monocentric. 
Moreover, they mingled AAV patients with manifesta-
tions related to vasculitis activity, and those with mani-
festations not related to it. Finally, data for AAV patients 
admitted to the intensive care unit (ICU) for AAV mani-
festations [20–24] are scarce and the prognosis of this 
specific population remains poorly determined.
We conducted this retrospective multicentric study 
to analyze disease presentation and outcome in AAV 
patients admitted to the ICU with acute vasculitis mani-
festations. Specifically, we intended to explore whether 
ICU admission was associated with adverse long-term 
outcomes. To this end, ICU-AAV patients were com-
pared with a group of AAV patients admitted to two 
nephrology departments with an active disease but with 
no requirement of ICU care (non-ICU-AAV patients).
Methods
Population and inclusion criteria
We conducted a multicentric retrospective study in 
seventeen ICUs from French University and Gen-
eral Hospitals, and from Lausanne’s University Hos-
pital in Switzerland. Inclusion criteria included: over 
18  years of age, ICU admission between January 2002 
and December 2012, and newly diagnosed or relapsing 
AAV. Only patients with acute vasculitis manifestations 
were included in the study. To be included, AAV ini-
tial or relapse diagnosis had to be done during the ICU 
stay or within the thirty days immediately prior to ICU 
admission.
A number of non-ICU-AAV patients were used as a 
control group. This group included all consecutive AAV 
patients of two nephrology centers (Angers and Tours 
University Hospitals), who were diagnosed between 
January 2002 and December 2012. To be included in the 
control group, patients had to show active newly diag-
nosed or relapsing AAV. Patients who required further 
ICU admission within the month following admission to 
the nephrology department were excluded from the con-
trol group.
ANCA positivity by indirect immunofluorescence 
(cytoplasmic or perinuclear pattern) and ELISA (protein-
ase-3 (PR-3) or myeloperoxidase (MPO)) was required 
for inclusion in both groups (ICU and non-ICU groups).
The Institutional Ethics Committees of the Angers 
University Hospital and Lausanne Hospital approved the 
study protocol (N°2013/21 and N°164/14, respectively).
AAV diagnosis
Patients’ medical files were analyzed, and the AAV sub-
type (GPA, MPA and EGPA) was determined according 
to the European Medicines Agency vasculitis classifica-
tion algorithm [25]. For newly diagnosed patients, the 
date of AAV diagnosis was defined as the date of ANCA 
determination and the date of relapse for relapsing 
patients was defined as the date of hospital admission. 
The diagnosis of new onset AAV relied on ANCA positiv-
ity and presence of vasculitis manifestations. The diagno-
sis of relapsing AAV was retained when it was suspected 
by the physician, and when the retrospective analysis of 
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the patient’s medical history was consistent (i.e., typical 
clinical manifestation, increase in ANCA titer or biopsy-
proven vasculitis activity).
For conflicting cases, the hospitalization report and 
the medical records were analyzed by 2 expert investiga-
tors (JFA and NL). If AAV activity remained doubtful, the 
patient was excluded from the study.
Data collection
Patients were identified from the ICU database of each 
hospital. All the data were collected retrospectively by a 
systematic screening of patients’ medical records. The fol-
lowing data were collected: age, gender, height and weight, 
and significant aspects of past medical history. Organs 
affected by vasculitis were listed upon the presentation of 
newly diagnosed and relapsing patients. The ANCA type 
was recorded, and pathology data of biopsied organs were 
analyzed (when available) to confirm the diagnosis of vas-
culitis. Birmingham Vasculitis Activity Score (BVAS) 2003 
was used to determine AAV activity [26].
ICU ANCA‑associated vasculitis
For ICU-AAV patients, causes of ICU admission with 
simplified acute physiology score II (SAPS II) and 
sequential organ failure assessment (SOFA) score upon 
admission [27, 28] were recorded. The ratio of partial 
pressure of arterial oxygen over inspired-fraction of oxy-
gen  (PaO2/FiO2) with ventilation initiation, the serum 
creatinine level and the Acute Kidney Injury Network 
(AKIN) score [29] upon ICU admission were used to 
characterize the severity of respiratory and renal injuries. 
Supporting therapies used during the ICU stay and their 
duration (mechanical ventilation, renal replacement ther-
apy, vasopressors), septic events (as documented in the 
ICU hospitalization report) and death were registered. 
Cause of death was classified by two authors (NL and JD) 
after patient’s files review.
AAV treatment
In both groups, all specific AAV induction regimens 
and their timing were recorded, including steroid treat-
ment, cyclophosphamide, rituximab and plasmapheresis 
treatments. The use of steroid boluses, and the dosages 
and the number of cyclophosphamide and rituximab 
boluses were analyzed, as well as the number of plasma 
exchanges.
Outcomes definition
For both groups, survival was analyzed until death, loss 
of follow-up or end of follow-up (December 2012). Sur-
vival free of end-stage renal disease of the ICU and non-
ICU groups was also analyzed. Renal death was defined 
as the need for long-term (>3 months) renal replacement 
therapy.
Statistical analysis
Quantitative parameters were presented as median 
(interquartile range (IQR)) and qualitative parameters 
as absolute number and/or percentage. Categorical and 
continuous data were analyzed with Chi-square (or Fish-
er’s exact test) and Mann–Whitney U tests, respectively. 
Results were presented as odd ratio (OR) with 95% confi-
dence intervals (95 CIs); the Kaplan–Meyer method was 
used to analyze the survival rates of ICU and non-ICU 
groups. A log-rank test was used to compare the survival 
curves. All statistical tests were performed with a two-
sided 0.05 level of significance applied. Statistical analysis 
was performed using SPSS  software® 23.0 for Macintosh 
and Graphpad  Prism®.
Results
Baseline characteristics of the ICU and non‑ICU‑AAV 
populations
Ninety-seven and ninety-five AAV patients with a median 
follow-up of 2.28 [IQR 0.2–4.7] and 4.18 [IQR 1.7–7.0] 
years were included in the ICU group and the non-ICU 
control group, respectively. Characteristics of the ICU 
and the non-ICU groups and the main AAV manifesta-
tions upon admission are detailed in Table 1. Groups were 
similar regarding gender and AAV subtype, but patients 
of the ICU group were significantly younger. Newly diag-
nosed AAV was significantly more common in the non-
ICU group (93%) compared with the ICU group (79%). 
In the ICU group, 39 patients were diagnosed during the 
ICU stay and 58 were diagnosed before their admission to 
ICU. Disease activity assessed by BVAS showed no statis-
tical difference between groups. Heart, lung and central 
neurological injuries were more frequent in ICU patients 
than in non-ICU patients. A notably high rate of alveolar 
hemorrhage was observed in ICU patients (64 vs. 10% in 
non-ICU patients), but the renal involvement rate was 
comparable. ANCA subtypes by immunofluorescence 
and ELISA were significantly different between groups. 
Indeed, 62% of ICU patients had PR3-ANCAs, and 68% of 
non-ICU patients had MPO-ANCAs.
Parameters specific to AAV‑ICU group and assessment 
of organ support
The median ICU length of stay was 7 [IQR 4.5–17.5] days. 
Acute respiratory failure (alone or in combination with 
renal failure) was the main cause for ICU admission and 
accounted for 80% of ICU admissions. Approximately 70% 
of patients required respiratory assistance, which was ini-
tiated within 48  h following ICU admission in the large 
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majority of the patients. Acute kidney injury was highly 
prevalent, with AKIN score ≥1 in more than 90% of 
patients at the time of admission, and more than half of the 
patients required renal replacement therapy (RRT) during 
their ICU stay. RRT was initiated within 48 h after admis-
sion in 35% of patients. Vasopressors were required for 25% 
of the patients. Infection events were reported in 40% of the 
patients during the ICU stay, with an identified pathogen in 
82% of them. These data are summarized in Table 2. 
Site and nature of infectious events are detailed in 
Additional file 1: Table 1.
Immunosuppressive regimens
Ninety-nine percent of patients of the ICU and 98% of 
non-ICU groups received glucocorticoids for remis-
sion induction. Steroid pulses were given to 95 of the 
97 (98%) patients in the ICU group, and to 80 of the 95 
(84%) patients in the non-ICU group (p  <  0.001). Glu-
cocorticoids were combined with cyclophosphamide 
in 83 (85.6%) ICU patients and in 78 (82.1%) non-ICU 
patients (p = 0.514). PE was more frequently used in the 
ICU group than in the non-ICU group (n = 48, 54% vs. 
n = 23, 24%, respectively, p < 0.001).
Table 1 Baseline characteristics of the ICU and non-ICU ANCA-associated vasculitis groups
ICU‑AAV (n = 97) Non‑ICU‑AAV (n = 95) p
Baseline characteristics
 Sex (M/F) 45/52 54/41 0.147
 Age (years) 62.0 (48.0–71.0) 68.0 (55.8–75.1) 0.016
 Weight (kg) 71.5 (58.0–80.0) 70.0 (60.0–82.0) 0.877
 Hypertension, n (%) 35 (36.1) 47 (49.5) 0.061
 Diabetes mellitus, n (%) 11 (11.3) 9 (9.5) 0.672
AAV characteristics
 Diagnosis, n (%)
 GPA 58 (59.8) 45 (47.4) 0.084
 MPA 37 (38.1) 48 (50.5) 0.084
 EGPA 2 (2.1) 2 (2.1) 0.983
ANCA type
 By immunofluorescence
  cANCA, n (%) 61 (62.9) 33 (34.7) <0.001
  pANCA, n (%) 36 (37.1) 62 (65.3) <0.001
 By ELISA
  PR3‑ANCA, n (%) 60 (61.9) 30 (31.6) <0.001
  MPO‑ANCA, n (%) 37 (38.1) 65 (68.4) <0.001
Disease status, n (%)
 Newly diagnosed AAV, n (%) 77 (79.4) 88 (92.6) 0.008
 Relapsing AAV, n (%) 20 (20.6) 7 (7.4) 0.008
 BVAS 23.0 (18.0–27.5) 19.5 (15.0–31.0) 0.273
Organ involvement, n (%) when specified
 Cutaneous signs 25 (25.8) 19 (20.0) 0.341
 Ear, nose, throat 36 (37.1) 34 (35.8) 0.849
 Heart 17 (17.5) 3 (3.2) 0.001
 Digestive 9 (9.3) 3 (3.2) 0.134
 Lung 85 (87.6) 30 (31.6) <0.001
  Alveolar hemorrhage 62 (63.9) 9 (9.5) <0.001
  Others 23 (23.7) 21 (22.1) 0.791
 Renal 83 (85.6) 87 (91.6) 0.191
  Serum creatinine 256.5 (115.3–527.8) 244.0 (132.0–377.5) 0.666
  Renal replacement therapy 55 (56.7) 19 (20.0) <0.001
 Neurological 25 (25.8) 12 (12.6) 0.020
  Central 8 (8.2) 0 (0) 0.007
  Peripheral 17 (17.5) 12 (12.6) 0.343
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The most common induction immunosuppressive regi-
men administered to the ICU group was a combination 
of glucocorticoids and cyclophosphamide used in 41 
patients (42.3%) and a combination of glucocorticoids, 
cyclophosphamide and PE used in 42 patients (43.3%). In 
the non-ICU group, glucocorticoids and cyclophospha-
mide were the most frequent induction regimen (58.9% 
of patients). Data detailing immunosuppressive regimen 
used in ICU and non-ICU-AAV patients, and their tim-
ing according to ICU admission, are outlined in Addi-
tional file 2: Table 2.
Mortality and predictors of ICU mortality
Fifteen patients (15.5%) died during the ICU stay. SAPS 
II and ICU SOFA scores were significantly higher in non-
survivors compared to survivors. The need for mechani-
cal ventilation (invasive or not) and vasopressors was 
more frequent in the non-survivor group. The require-
ment of RRT tended to be higher in the non-survivor 
group, but remained statistically not significant. Moreo-
ver, infectious events during ICU stays were significantly 
more prevalent in non-survivors. Non-surviving patients 
received cyclophosphamide more frequently than surviv-
ing patients. We did not observe any difference between 
survivors and non-survivors according to the timing of 
immunosuppressive treatment, including cyclophospha-
mide, with respect to ICU admission (data not shown). 
These data are summarized in Table 3. In a multivariate 
logistic analysis, cyclophosphamide was no longer asso-
ciated with mortality after adjustment on SAPS II or 
occurrence of infection events (Additional file 3: Table 3).
The cause of ICU death was attributed to refractory 
vasculitis manifestations in 6 (40%) patients (DAH in 5 
patients, digestive involvement in 1), to multiple organ 
failure likely due to sepsis in 5 (33%) patients and to neu-
rologic causes in 4 (27%) patients, including 3 cerebral 
hemorrhage while receiving anticoagulation for extracor-
poreal membrane oxygenation.
Long‑term outcomes of ICU‑AAV patients
Whether ICU stay can impact the prognosis of AAV 
patients had not been yet analyzed. Regarding hospi-
tal mortality, we observed that ICU-AAV patients had a 
poorer survival rate compared to non-ICU-AAV patients 
(Fig.  1a). Given that most deaths in the ICU group 
occurred soon after ICU admission, we next analyzed the 
long-term mortality of patients that survived to the first 
hospital stay (ICU or non-ICU patients). By this way, we 
were able to observe that the long-term mortality of AAV 
patients who survived to the first hospital stay was no 
longer different between the ICU and the non-ICU group 
(Fig. 1b). We also analyzed the renal outcome of groups. 
Long-term renal outcome was available for 67 ICU-AAV 
patients out of 82 and for all non-ICU-AAV patients. 
Survival analysis showed that renal survival was not sig-
nificantly different between ICU and non-ICU patients 
after 1 year of follow-up (Fig. 1c).
Discussion
In the present work, we described 97 patients who 
required ICU admission at AAV diagnosis or relapse. 
Lung involvement (notably, DAH) was the prominent 
cause for ICU admission, 70% of the patients requir-
ing mechanical ventilation. Fifty percent needed RRT 
and 25% needed vasopressors. Comparison with a 
Table 2 Characteristics and  supportive therapies used 
with ICU-AAV patients
* Diagnosed < or >48 h after ICU admission
**Among patients that experienced infection
Length of stay (days) 7.0 (4.5–17.5)
Reasons for ICU admission, n (%)
 Respiratory failure 44 (45.4)
  And renal failure 23 (23.7)
  And neurological failure 1 (1.0)
 Acute renal failure 17 (17.5)
  And neurological failure 4 (4.1)
 Neurological failure 4 (4.1)
 Heart failure 3 (3.1)
 Hemorrhagic shock 1 (1.0)
SOFA (at admission) 6 (4.0–9.0)
SAPS II 39.0 (31.0–51.0)
Respiratory assistance, n (%)
 Mechanical ventilation
  Invasive or/and noninvasive 66 (68.0)
    Within 48 h of admission 58 (59.8)
  Noninvasive ventilation only 19 (19.6)
  Invasive ventilation only 36 (37.1)
  Noninvasive and invasive ventilation 11 (11.3)
 Length of respiratory assistance (days) 10.0 (5.5–18.5)
 PaO2/FiO2 92.0 (58.8–182.0)
Kidney involvement
 Serum creatinine at admission, (μmol/L) 256.5 (115.3–527.8)
 Maximum serum creatinine in ICU, (μmol/L) 348.0 (160.0–673.0)
 AKIN score ≥1, n (%) 89 (91.8)
 Renal replacement therapy, n (%) 55 (56.7)
  Within 48 h of admission 34 (35.1)
Hemodynamic assistance
 Vasopressive amines, n (%) 26 (26.8)
  Within 48 h 25 (25.8)
 Length of treatment (days) 6.0 (3–11.5)
Infectious events
 Early/late* 29/10
  Lung infection, n (%) 29 (74.4)**
  Other sites, n (%) 10 (25.6)**
  Patients with pathogen identified, n (%) 32 (82.1)**
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control group of AAV patients admitted to the nephrol-
ogy department showed no difference in overall score of 
disease activity (BVAS), but ICU patients were younger 
and more likely to have PR3-ANCAs and GPA. A vast 
majority of ICU patients and non-ICU patients received 
an induction regimen with corticosteroid and cyclophos-
phamide, and ICU patients received PE more frequently. 
One-year mortality rate was higher in ICU patients due 
Table 3 Comparison between  survivor and  non-survivor ICU-AAV patients and  univariate logistic regression analysis 
for ICU mortality
OR odd ratio, CI confidence interval, ANCA anti-neutrophil cytoplasmic antibodies, c-ANCA cytoplasmic ANCA, AAV ANCA-associated vasculitis, CNS central nervous 
system, ENT ear nose throat, AKIN acute kidney injury network score, RRT renal replacement therapy, DAH diffuse alveolar hemorrhage
* Started before or during the ICU stay
Survivors (n = 82) Non‑survivors (n = 15) p value Univariate logistic regression
OR 95% CI p
Baseline characteristics
 Gender (female), n (%) 41 (50) 4 (26.7) 0.158 0.36 0.11–1.24 0.105
 Age (years), median [IQR] 61.0 [47.0–70.3] 67.0 [65.0–75.0] 0.212 0.98 0.94–1.02 0.311
 Hypertension, n (%) 32 (39.0) 3 (20.0) 0.158 0.39 0.10–1.49 0.169
 ANCA
  c‑ANCA type, n (%) 54 (65.9) 7 (46.7) 0.157 0.45 0.15–1.38 0.164
 AAV relapse, n (%) 19 (23.2) 1 (6.7) 0.185 0.24 0.03–1.92 0.177
AAV involvement
 Heart, n (%) 14 (17.1) 3 (20.0) 0.723 1.21 0.30–4.87 0.784
 CNS, n (%) 5 (6.1) 3 (20.0) 0.104 3.85 0.81–18.2 0.089
 Digestive, n (%) 7 (8.5) 2 (13.3) 0.626 1.64 0.31–8.83 0.559
 ENT, n (%) 33 (40.2) 3 (21.4) 0.159 0.37 0.10–1.41 0.147
Kidney
  Serum creatinine (µmol/L), median [IQR] 364.0 [117.5–503.0] 229.0 [104.0–682.0] 0.824 1.00 0.99–1.00 0.878
  AKIN > 1, n (%) 74 (90.2) 15 (100) 0.351 1.51 0.17–13.1 0.706
  RRT, n (%) 43 (52.4) 12 (80.0) 0.086 3.53 0.93–13.5 0.064
 Lung, n (%) 71 (86.6) 14 (93.3) 0.685 2.17 0.26–18.2 0.475
  DAH, n (%) 51 (62.2) 11 (73.3) 0.562 1.67 0.49–5.71 0.412
  Respiratory assistance, n (%) 52 (63.4) 14 (93.3) 0.032 8.51 1.07–67.9 0.043
Infectious event, n (%) 26 (31.7) 13 (86.7) <0.001 14.0 2.94–66.6 0.001
Vasopressors, n (%) 17 (20.7) 9 (60.0) 0.002 5.73 1.79–18.4 0.003
Plasma exchange*, n (%) 39 (47.6) 7 (46.7) 0.949 0.96 0.32–2.91 0.949
Cyclophosphamide*, n (%) 52 (63.4) 14 (93.3) 0.032 8.51 1.07–67.9 0.043
SAPS II, median [IQR] 37.5 [28.8–49.3] 52.0 [33.0–66.0] 0.006 1.06 1.02–1.10 0.003
SOFA, median [IQR] 6.0 [4.0–9.0] 8.0 [6.0–13.0] 0.040 1.21 1.04–1.41 0.013
BVAS, median [IQR] 23.0 [18.0–28.0] 21.0 [20.0–27.0] 0.916 1.01 0.94–1.08 0.899
Fig. 1 a Survival of ICU and non‑ICU‑AAV patients and b survival of patients who survived to the first hospital stay. c Renal survival of ICU and non‑
ICU patients. Survivals were compared using the log‑rank test
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to high in-ICU fatality (15.5%) but, interestingly, in ICU 
survivors, 1-year survival after initial hospital admission 
was no different from non-ICU patients.
Several studies have already reported AAV patients 
admitted to ICU. Most included AAV patients admitted 
to ICU for reasons related to vasculitis manifestations 
and reasons unrelated to the same—such as our results 
cannot be readily compared. However, some of our 
results are in line with these reports, showing a majority 
of GPA among ICU-AAVs [20, 21, 30], and a high preva-
lence of DAH [20, 21, 24]. Previous studies have reported 
very variable rates of respiratory assistance (31–57%) 
[20, 23, 24, 31] and of RRT use (20–80%) [20, 23, 24], and 
variable mortality rates from 0 to 33% probably related to 
the heterogeneity of included patients [20, 23].
However, this study is the first to report on any long-
term outcome of AAV patients with active disease after 
an ICU stay or to assess the impact of ICU stay in com-
parison with AAV patients initially admitted to non-ICU 
wards. Indeed, besides observing that ICU admission 
for acute organ dysfunction requiring organ support is 
associated with poor outcome, we thought that the main 
question was to determine the association between ini-
tial disease severity, invasive therapeutic procedures, 
and long-term outcome. Given that kidney involvement 
is a major prognostic factor in AAV [11], we estimated 
that AAV patients with kidney involvement constituted 
a pertinent control group. Unsurprisingly, a high death 
rate was observed with ICU patients at the early phase of 
the disease, but the observation that long-term outcome 
(both mortality and renal survival) in ICU survivors is 
no different from non-ICU patients is a key observation 
and deserves discussion. First, it can be noted that ICU 
patients were younger and more frequently had GPA 
compared with MPA, two factors related to better out-
come in previous studies outside the ICU [32, 33]. The 
fact that GPA onset is usually earlier than MPA onset 
may explain the lower age and the greater frequency of 
patients with relapsing in the ICU group [33]. Due to the 
low death rate after the initial stay, no multivariate analy-
sis to determine the association between ICU admission 
or not, AAV type and age with outcome was attempted. 
Beyond these limitations, our observation tends to show 
that initial disease severity, once adequately controlled 
by the induction regimen, is not associated with adverse 
long-term outcome and does not indicate a more severe 
disease. From an ICU point of view, it should be noted 
that this observation is at stake with several reports 
showing prolonged excess risk of death in ICU survivors 
in comparison with non-ICU patients [34]. Although the 
number of patients in our study limits the interpreta-
tion of this result, it favors the hypothesis that prolonged 
mortality in ICU patients is related to baseline conditions 
(here: the AAV disease) rather than to acute episodes 
[35].
Notwithstanding the relatively good prognosis with 
ICU survivors, ICU mortality is a concern that should be 
addressed. Intensity of acute organ dysfunction assessed 
through acute severity scores (SOFA, SAPS II and hence 
organ support requirement), cyclophosphamide and 
infection were associated with ICU death. In contrast, 
BVAS did not appear suitable for predicting short-term 
mortality of ICU-AAV patients [20]. Despite limita-
tion of statistical analysis, cyclophosphamide did not 
appear as a risk factor for mortality after adjustment on 
SAPS II and infection occurrence. Although association 
between organ dysfunction and mortality is trivial in the 
ICU setting, the association between cyclophosphamide, 
infection and mortality is certainly not straightforward. 
Indeed, most infections were nosocomial infections in 
patients receiving mechanical ventilation, and the attrib-
utable mortality of such infections has been debated [36, 
37]. Rather, it may represent an indicator of overall sever-
ity associated with an immunosuppressive state related 
to the condition which led to ICU admission (DAH and 
AAV), consequences of ICU care (tracheal intubation), 
and immunosuppressive treatments. Analysis of cause of 
death brings up additional relevant information, as infec-
tion causes and disease activity both represent the two 
major conditions associated with death. Finally, from our 
dataset, no straightforward message can be established 
for the purpose of determining whether ICU patients 
with AAV require a higher or lower level of immunosup-
pression, if this concept has any meaning.
Improved ICU outcome may come from more refined 
and individualized induction regimen. It has been proven 
that PE has benefited AAV patients with severe renal 
involvement (i.e., creatinine >500  μmol/L) when used 
in replacement of methylprednisolone boluses in AAV 
induction treatment, allowing the achievement of higher 
rates of renal recovery [11]. Moreover, evidence from 
clinical practice and retrospective studies also supports 
PE effectiveness in patients with DAH-related AAV [5, 
12, 38]. However, our study does not show a clear-cut 
impact of PE on survival, this observation being clearly 
limited by the design of this study and the dataset. It 
should be noted that rituximab, which appeared as a 
novel option in both induction and maintenance regi-
mens [14, 15] of AAV [39], was rarely used in our study. 
This may be explained by the date range of the study 
which ended in 2012, whereby rituximab was not able to 
pass into clinical practice. Given the limited data related 
to the use of rituximab in patients with severe forms of 
AAV including patient with DHA, The French Vasculitis 
Study Group recommended to use cyclophosphamide as 
a first-line treatment to induce remission [40]. However, 
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recently, Cartin-Ceba et al. [41] suggested in a retrospec-
tive analysis that rituximab may be superior to cyclo-
phosphamide to achieve remission at 6  months in AAV 
patients with DHA. We observed a high rate of infectious 
events, a majority of deaths related to DAH or sepsis in 
our study and an increased rate of cyclophosphamide use 
in non-survivors. Whether using rituximab in replace-
ment of cyclophosphamide in this specific population 
may improve prognosis merits to be considered.
Our study undeniably has several limitations, start-
ing with its retrospective design and restriction to AAV 
patients with ANCA positivity. Despite all efforts to 
be as exhaustive as possible, some data may have been 
missed. Given the very low prevalence of ICU admission 
for active AAV, a prospective study does not seem eas-
ily conceivable. We believe that the multicentric and con-
trolled design of our study has contributed to limitation 
of center-dependent bias and to significant expansion of 
ICU-AAV-related knowledge, especially with regard to 
long-term prognosis of these patients.
Conclusion
Acute respiratory failure due to DAH is the most com-
mon vasculitis manifestation which puts AAV patients in 
the ICU. Despite a high early ICU mortality rate, patients 
who survive to ICU show comparable long-term mor-
tality and renal prognosis compared to non-ICU-AAV 
patients.
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